Ardelyx Reports Third-Quarter Revenue of $125.5 Million, Up 19%
Ardelyx reported total product revenue of $125.5 million for the quarter ended September 30, 2026, up 19% from the same period in 2025. The company reiterated full-year 2026 revenue and operating expense guidance.
Ardelyx reported total product revenue of $125.5 million for the third quarter ended September 30, 2026, representing a 19% increase compared to the same period in 2025. The company ended the quarter with $285.3 million in cash, cash equivalents, and short-term investments. Research and development expenses for the quarter were $25.2 million. Ardelyx reiterated its full-year 2026 revenue guidance for both IBSRELA and XPHOZAH, as well as its operating expense guidance, while maintaining its long-term revenue goal of $1 billion for IBSRELA.